Figure 5.
SAR443809 demonstrates a sustained inhibition of AP activity when dosed in vivo in cynomolgus monkeys. (A) Percent AP activity measured over time in serum samples from monkeys dosed with PBS (control arm) intravenously, as measured by Wieslab EIA ex vivo. (B-C) Percent AP activity measured over time in serum samples from monkeys dosed with SAR443809 (B) intravenously or (C) subcutaneously, as measured by Wieslab EIA ex vivo. The dashed lines represent a threshold of 90% AP inhibition. Group average (n = 4) ± standard deviation for each timepoint is shown.

SAR443809 demonstrates a sustained inhibition of AP activity when dosed in vivo in cynomolgus monkeys. (A) Percent AP activity measured over time in serum samples from monkeys dosed with PBS (control arm) intravenously, as measured by Wieslab EIA ex vivo. (B-C) Percent AP activity measured over time in serum samples from monkeys dosed with SAR443809 (B) intravenously or (C) subcutaneously, as measured by Wieslab EIA ex vivo. The dashed lines represent a threshold of 90% AP inhibition. Group average (n = 4) ± standard deviation for each timepoint is shown.

Close Modal

or Create an Account

Close Modal
Close Modal